Recap: Integra Lifesciences Q2 Earnings

 

Shares of Integra Lifesciences IART were unchanged after the company reported Q2 results.

Quarterly Results

Earnings per share increased 139.39% over the past year to $0.79, which beat the estimate of $0.66.

Revenue of $389,992,000 higher by 50.77% from the same period last year, which beat the estimate of $376,010,000.

Guidance

Q3 EPS expected between $0.71 and $0.74.

Q3 revenue expected to be between $382,000,000 and $389,000,000.

How To Listen To The Conference Call

Date: Jul 28, 2021

Time: 08:30 AM

ET Webcast URL: https://investor.integralife.com/events-and-presentations

Technicals

52-week high: $77.40

52-week low: $42.12

Price action over last quarter: down 5.16%

Company Description

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and orthopedics and tissue technologies. Codman specialty surgical generates maximum revenue from its segmental operations. Integra earns approximately 29% of sales internationally, with the remainder 71% derived from the United States.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!